Streetbeat News

Products Services

EVLV

Evolv Technology (NASDAQ:EVLV) has been awarded a patent by the USPTO for its unique weapons detection technology used in its flagship product, Evolv Express. This patent, which classifies objects as threats or non-threats using RF electromagnetic data, adds to Evolv's growing portfolio of over 30 issued patents. The technology is deployed in various public spaces globally.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:14 pm

BTCUSD

In a recent interview between former President Donald Trump and Elon Musk, Trump avoided discussing Bitcoin or cryptocurrency, despite high expectations and significant wagers on prediction markets. The interview, which faced a delay attributed to a possible DDoS attack on X, attracted over 1 million listeners. One bettor made over $1 million by correctly predicting Trump's avoidance of the topic.

Portfolio Pulse from Murtuza Merchant

August 13, 2024 | 12:11 pm

GAME

Zoned and 5-hour ENERGY have launched a Flavor Wars Streamer Competition, allowing fans to represent their favorite streamer in Fortnite and win a $10,000 cash prize.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:08 pm

ENVB

Enveric Biosciences and Aries Science & Technology have announced the issuance of a key U.S. patent for a topical product aimed at treating radiation dermatitis. The patent strengthens Enveric's portfolio and is part of a Licensing Agreement between Enveric's subsidiary Akos Biosciences and Aries. The market opportunity for this treatment is estimated at $400 million annually.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:08 pm

GM

General Motors (GM) is recalling nearly 22,000 Cadillac Lyriq electric SUVs due to a software defect that may cause a loss of braking ability. The recall affects model years 2023-2024 and will be addressed via a software update. No injuries or fatalities have been reported.

Portfolio Pulse from Anan Ashraf

August 13, 2024 | 12:07 pm

VUZI

Vuzix Corporation (NASDAQ:VUZI) has developed a new micro-touch manufacturing technique for its optical waveguide fabrication processes, which will enhance optical performance, increase yields, and boost production rates.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:07 pm

URGN

UroGen Pharma announced that the latest Duration of Response (DOR) data is expected to support a New Drug Application (NDA) for UGN-102, targeting low-grade intermediate-risk non-muscle invasive bladder cancer. The company plans to complete the NDA submission soon, with a potential FDA decision as early as Q1 2025, assuming priority review.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm

APLM

Apollomics announced preliminary data from its Phase 2 SPARTA trial, showing a 43% objective response rate for Vebreltinib in patients with non-CNS MET fusion solid tumors.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm

UAMY

United States Antimony Corporation (UAMY) has acquired full ownership of 97 mining claims and 3 leases in Ontario's Sudbury District. This acquisition targets critical minerals such as cobalt, nickel, copper, and bismuth, aligning with Canada's billion-dollar plan to boost its critical minerals sector.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm

NRBO

NeuroBo Pharmaceuticals has completed enrollment for the Single Ascending Dose (SAD) part of its Phase 1 trial for the obesity treatment DA-1726. No significant issues were encountered, allowing for an accelerated start to the Multiple Ascending Dose (MAD) part. Top-line data for SAD is expected in Q3 2024, and MAD data in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:04 pm